Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC

Video

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Once a drug has shown activity as a single agent, it is typically evaluated in combination, explains Grivas. Such was the rationale for a phase I/II study (NCT02522715) with the chemotherapy agent cabazitaxel and the novel antiandrogen enzalutamide, which are both approved for use as monotherapy in mCRPC.

In the phase I portion of the trial, no dose-limiting toxicities were observed with the combination. The phase II results, which were presented at the 2020 Genitourinary Cancers Symposium, showed encouraging prostate-specific antigen (PSA) response rates with the combination with a manageable safety profile, says Grivas. Among 36 evaluable patients, 56% had a ≥90% decrease in PSA. These results merit further investigation in a phase III trial, concludes Grivas.

Related Videos
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD
Sumanta Kumar Pal, MD, FASCO,
Carrie L. Kitko, MD
Kara N. Maxwell, MD, PhD
Kian-Huat Lim, MD, PhD
Thomas F. Gajewski, MD, PhD
Michelle Krogsgaard, PhD
Lori A. Leslie, MD